- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01260584
The Influence of Smoking Status on Prasugrel and Clopidogrel Treated Subjects Taking Aspirin and Having Stable Coronary Artery Disease
The Influence of Smoking Status on the Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel in Aspirin-treated Subjects With Stable Coronary Artery Disease
This study is being conducted to determine if smoking will influence the platelet aggregation inhibition ability of clopidogrel and prasugrel. It will also determine if smoking has any effect on the plasma concentrations of the active metabolite of prasugrel and the active and inactive metabolites of clopidogrel.
The primary hypothesis is that smoking status will influence the antiplatelet effects and active metabolite concentrations of clopidogrel but will have no impact on prasugrel's antiplatelet effects or active metabolite concentrations.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21215
- Sanai Center for Thrombosis Research
-
-
Ohio
-
Cincinnati, Ohio, United States, 45212
- Medpace Clinical Pharmacology Unit
-
Cincinnati, Ohio, United States, 45219
- The Carl and Edyth Lindner Center for Research and Education at The Christ Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female subjects > or = 18 years and <75 years of age;
- Weight > or = 60 kg;
- On aspirin therapy (81 mg to 325 mg daily) at the time of screening and able to maintain a consistent aspirin dosing regimen from the baseline visit through the final study visit;
Subjects who do not have contraindications for a thienopyridine (ie, prasugrel, clopidogrel, or ticlopidine) and have a history of stable atherosclerosis represented by CAD, defined as any of the following:
- Chronic stable angina;
- Documented prior ACS event > or = 30 days before screening and not currently prescribed or currently on thienopyridine therapy;
- Previous coronary revascularization including percutaneous transluminal coronary angioplasty, stent, or coronary artery bypass graft;
- Coronary Artery Disease (> or = 40% obstruction) in at least one coronary vessel after angiography;
- Documented history of positive stress test; or
- High coronary artery calcium score (> or = 90th percentile for age and gender) determined by cardiac computed tomography scan;
- Current smokers who smoke > or = ½ pack per day of cigarettes with a NicAlert™ level of 6;
- Non-smokers with a NicAlert level of 0, 1, or 2;
Female subjects who meet one of the following:
- Women of childbearing potential with a negative serum pregnancy test at screening, who are not breastfeeding, do not plan to become pregnant during the study, and agree to use an approved method of birth control during the study. Approved methods of birth control are intrauterine device, diaphragm plus spermicide, or female condom plus spermicide. Abstinence, partner's use of condoms, partner's vasectomy, and hormonal contraceptives are NOT acceptable methods of contraception;
- Women who have been postmenopausal for at least 1 year or have had a hysterectomy, bilateral salpingo-oophorectomy, or tubal ligation at least 6 months prior to signing the Informed Consent Form (ICF); and
- Subjects with a competent mental condition to provide written informed consent before entering the study.
Exclusion Criteria:
- Subjects who received a bare metal stent and/or a drug-eluting stent within the last 12 months;
- Subjects who have had an angiogram < or = 7 days before randomization;
- Any other formal indication for the use of a thienopyridine;
- Subjects with a history of refractory ventricular arrhythmias;
- Subjects with a history of an implantable defibrillator device;
- Subjects with a history or evidence of congestive heart failure (New York Heart Association Class III or above) within 6 months prior to screening;
- Subjects with significant hypertension (systolic blood pressure >180 mmHg or diastolic blood pressure >110 mmHg) at either the time of screening or baseline assessment;
Bleeding risk exclusion criteria:
- Any known contraindication to treatment with an anticoagulant or antiplatelet agent;
- Prior history or clinical suspicion of cerebral vascular malformations, intracranial tumor, transient ischemic attack, or stroke, or recent history (within 3 months) of head trauma;
- Prior history or presence of significant bleeding disorders (eg, hematemesis, melena, severe or recurrent epistaxis, hemoptysis, hematuria, or intraocular bleeding);
- History (within the last 5 years) or presence of gastric ulcers. Previous history of duodenal ulcer is acceptable but must have been successfully surgically or medically treated with no further evidence of disease in the past 6 months (from screening);
- Prior history of abnormal bleeding tendency (ie, prolonged bleeding on dental extraction, tonsillectomy, or previous surgical procedure);
- Known prior history or presence of thrombocytopenia (platelet count <100,000/mm3) or thrombocytosis (platelet count >500,000/mm3) or recent history (within 6 months) of hemoglobin <10 mg/dL;
- International normalized ratio (INR) >1.5 or activated partial thromboplastin time (aPTT) > upper limit of normal (ULN) of laboratory reference range at screening;
- History of major surgery, severe trauma, fracture, or organ biopsy within 3 months prior to enrollment;
Prior/concomitant therapy exclusion criteria:
- Subjects taking prasugrel, clopidogrel, ticlopidine, cilostazol, dipyridamole, warfarin, heparin, direct thrombin inhibitors, or GPIIb/IIIa inhibitors < or = 10 days prior to randomization or during study participation;
- Use (or planned use) of fibrinolytic agents within 30 days before screening or during study participation;
- Subjects receiving treatment with nonsteroidal anti-inflammatory drugs or cyclooxygenase-2 inhibitors exceeding 3 doses per week;
- Subjects taking proton pump inhibitors (eg, lansoprazole, esomeprazole, omeprazole, pantoprazole, or rabeprazole) < or = 10 days prior to randomization or during study participation;
- Use or planned use of any herbal supplements < or = 10 days prior to randomization or during study participation;
- Use or planned use of the following strong inhibitors of various CYP pathways < or =10 days prior to randomization or during study participation: ciprofloxacin, cimetidine, fluvoxamine, estradiol, ethinylestradiol, fluconazole, amiodarone, indinavir, nelfinavir, ritonavir, saquinavir, clarithromycin, erythromycin, telithromycin, itraconazole, ketoconazole, fluconazole, nefazodone, or grapefruit-containing products;
- Use or planned use of the following strong inducers of various CYP pathways < or = 10 days prior to randomization or during study participation: rifampin, barbiturates, carbamazepine, dexamethasone, or St. John's Wort;
- Female subjects taking hormonal contraception or hormonal replacement therapy during study participation;
General exclusion criteria:
- Investigative site personnel directly affiliated with the study or immediate family of investigative site personnel directly affiliated with the study. Immediate family is defined as a spouse, parent, child, or sibling, whether biological or legally adopted;
- Daiichi Sankyo or Eli Lilly employees;
- Currently enrolled in, or discontinued within the last 30 days from, any clinical study involving an investigational drug or device;
- Have previously completed or withdrawn from this study;
- Women who are known to be pregnant and/or who receive a positive serum pregnancy test result, and/or who have given birth within the past 90 days, and/or who are breastfeeding;
- Results of clinical laboratory tests at the time of screening that are judged to be clinically significant for the subject, as determined by the Investigator;
- Known allergies or intolerance to aspirin and/or thienopyridines (prasugrel, clopidogrel, or ticlopidine);
- Evidence of significant active neuropsychiatric disease, alcohol abuse, or drug abuse, in the Investigator's opinion;
- Evidence of active hepatic disease or any of the following: positive human immunodeficiency virus antibodies; positive hepatitis C antibody; positive hepatitis B surface antigen; serum alanine transaminase, aspartate transaminase, or gamma-glutamyltransferase > or = 3 × ULN of laboratory reference range; or bilirubin > or = 2 × ULN of laboratory reference range at screening;
- Subjects who are unwilling to make themselves available for the duration of the study and who will not abide by the research unit policy and procedure and study restrictions.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Prasugrel
Prasugrel 10 mg film-coated tablet daily dose × 10 days.
To maintain blinding, placebo film-coated tablets matching clopidogrel in appearance will be given daily × 10 days to subjects in the prasugrel treatment group.
In addition, aspirin 81 mg to 325 mg daily will be taken.
|
One 10 mg film-coated, oral tablet daily x 10 days.
In addition, aspirin 81 mg to 325 mg daily will be taken.
Other Names:
|
Active Comparator: Clopidogrel
Clopidogrel 75 mg film-coated tablet daily dose x 10 days To maintain blinding, placebo film-coated tablets matching prasugrel in appearance will be given daily × 10 days to subjects in the clopidogrel treatment group.
In addition, aspirin 81 mg to 325 mg daily will be taken.
|
One 75 mg film-coated, oral tablet daily x 10 days.
In addition, aspirin 81 mg to 325 mg daily will be taken.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Inhibition of Platelet Aggregation (IPA) in Prasugrel-treated and Clopidogrel-treated Smokers and Non-smokers Following 9 Days of Maintenance Therapy.
Time Frame: Baseline to day 10 for Active Treatment Periods 1 and 2
|
IPA will be measured by the Accumetrics P2Y12 Assay Device.
Response will be assessed in P2Y12 Reaction Units and as Platelet Reactivity Index (vasodilator-stimulated phosphoprotein assay).
|
Baseline to day 10 for Active Treatment Periods 1 and 2
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assessment of P2Y12 Reaction Units (PRU) by Treatment and Smoking Status
Time Frame: Day 10 for Active Treatment Periods 1 and 2
|
Day 10 occurs in each treatment period at which time data collections are made. 12.1.4. Responders and Poor Responders Numerous studies have established an association between high on-treatment platelet reactivity with clopidogrel and an increased risk for post-PCI ischemic events. In this study, the percentages of "responders" and "poor responders" following treatment with prasugrel and clopidogrel were compared. Poor responders were defined based on an Accumetrics VerifyNow PRU >235 and a VASP PRI >50%, as assessed 24 hours after the 9th maintenance dose. |
Day 10 for Active Treatment Periods 1 and 2
|
Assessment of Vasodilator Stimulated Phosphoprotein (VASP) by Treatment and Smoking Status
Time Frame: Day 10 for Active Treatment Periods 1 and 2
|
Day 10 occurs in each treatment period at which time data collections are made.
Numerous studies have established an association between high on-treatment platelet reactivity with clopidogrel and an increased risk for post-PCI ischemic events.
In this study, the percentages of "responders" and "poor responders" following treatment with prasugrel and clopidogrel were compared.
Poor responders were defined based on an Accumetrics VerifyNow PRU >235 and a VASP PRI >50%, as assessed 24 hours after the 9th maintenance dose.
|
Day 10 for Active Treatment Periods 1 and 2
|
Responder Rate by Treatment and Smoking Status Based on P2Y12 Reaction Units (PRU) <= 235
Time Frame: Day 10 for Active Treatment Periods 1 and 2
|
Day 10 for Active Treatment Periods 1 and 2
|
|
Responder Rate by Treatment and Smoking Status Based on Platelet Reactivity Index (PRI) <= 50%
Time Frame: Day 10 for Active Treatment Periods 1 and 2
|
Numerous studies have established an association between high on-treatment platelet reactivity with clopidogrel and an increased risk for post-PCI ischemic events.
In this study, the percentages of "responders" and "poor responders" following treatment with prasugrel and clopidogrel were compared.
Poor responders were defined based on an Accumetrics VerifyNow PRU >235 and a VASP PRI >50%, as assessed 24 hours after the 9th maintenance dose.
|
Day 10 for Active Treatment Periods 1 and 2
|
Characterization of the Pharmacokinetics (PK) Area Under Curve (AUC)(0-Last) of the Active Metabolite of Prasugrel and the Active Metabolite of Clopidogrel in Smokers and Non-smokers
Time Frame: After dose on Day 10 of Active Treatment Periods 1 and 2
|
Blood samples for determination of plasma concentrations of the prasugrel active metabolite, clopidogrel active metabolite, and clopidogrel inactive metabolite will be collected following the administration of the 10th (last) maintenance dose of each of the 2 Active Treatment Periods at 0.5, 1, 2, 4, and 6 hours post-dose.
|
After dose on Day 10 of Active Treatment Periods 1 and 2
|
Characterization of the Pharmacokinetics (PK) Cmax of the Active Metabolite of Prasugrel and the Active Metabolite of Clopidogrel in Smokers and Non-smokers
Time Frame: After dose on Day 10 of Active Treatment Periods 1 and 2
|
After dose on Day 10 of Active Treatment Periods 1 and 2
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Arteriosclerosis
- Arterial Occlusive Diseases
- Coronary Artery Disease
- Myocardial Ischemia
- Coronary Disease
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Platelet Aggregation Inhibitors
- Purinergic P2Y Receptor Antagonists
- Purinergic P2 Receptor Antagonists
- Purinergic Antagonists
- Purinergic Agents
- Clopidogrel
- Prasugrel Hydrochloride
Other Study ID Numbers
- CS747S-B-U4002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- Study Protocol
- Statistical Analysis Plan (SAP)
- Informed Consent Form (ICF)
- Clinical Study Report (CSR)
- Analytic Code
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
IGLESIAS Juan FernandoUniversity of BernNot yet recruiting
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
Barts & The London NHS TrustImperial College London; Brunel UniversityNot yet recruitingCORONARY ARTERY DISEASE
-
Fundación EPICRecruitingCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Left Main Coronary Artery Disease | Coronary Artery StenosisSpain
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Coronary Artery Stenosis | Coronary Artery RestenosisBelgium
-
China National Center for Cardiovascular DiseasesRecruitingLeft Main Coronary Artery DiseaseChina
Clinical Trials on Prasugrel
-
Eli Lilly and CompanyDaiichi Sankyo, Inc.Completed
-
Maasstad HospitalDaiichi Sankyo, Inc.; MicroPort Orthopedics Inc.; Research Maatschap Cardiologen...CompletedCardiovascular DiseasesNetherlands
-
University of PatrasCompleted
-
Gyeongsang National University HospitalCompletedBleeding | Acute Coronary Syndrome | Platelet ThrombusKorea, Republic of
-
University of MilanCompleted
-
Medstar Health Research InstituteCompletedAcute Coronary SyndromeUnited States
-
University of FloridaCompletedCoronary Artery DiseaseUnited States
-
VA Office of Research and DevelopmentCompletedCoronary Artery BypassUnited States
-
Research Maatschap Cardiologen Rotterdam ZuidAbbott Medical DevicesRecruitingST Elevated Myocardial Infarction | Dual Antiplatelet TherapyNetherlands, Germany, Italy